Thermo Fisher Scientific Inc. logo

Thermo Fisher Scientific Inc. (TMO)

Market Closed
3 Jul, 20:00
NYSE NYSE
$
429. 33
+1.57
+0.37%
$
154.12B Market Cap
37.17 P/E Ratio
1.56% Div Yield
1,359,300 Volume
21.53 Eps
$ 427.76
Previous Close
Day Range
426.08 432.9
Year Range
385.46 627.88
Want to track TMO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 18 days
Report: Biotech Research Firm Thermo Fisher Considers Selling Diagnostics Business

Report: Biotech Research Firm Thermo Fisher Considers Selling Diagnostics Business

Biotechnology research firm Thermo Fisher Scientific is reportedly looking to sell part of its diagnostics business amid industrywide concerns about federal cutbacks in spending on research.

Pymnts | 2 weeks ago
Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition

Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition

TMO grapples with macro pressures, rising expenses and fierce competition, but bets on acquisitions to fuel recovery.

Zacks | 2 weeks ago
TMO Launches Next-Generation Mass Spectrometers: Stock to Gain?

TMO Launches Next-Generation Mass Spectrometers: Stock to Gain?

Thermo Fisher debuts two advanced MSs, Orbitrap Astral Zoom and Orbitrap Excedion Pro, to accelerate precision medicine and drug discovery breakthroughs.

Zacks | 1 month ago
Thermo Fisher: With A 30% Price Drop, Trump Legislation, And High Capex, Is It Undervalued?

Thermo Fisher: With A 30% Price Drop, Trump Legislation, And High Capex, Is It Undervalued?

The neutral DCF model implemented in this article suggests that Thermo Fisher is undervalued by 29.24%. Thermo Fisher has invested, on average, 16.51% of its revenues in capex between 2019 and 2024. Due to the significant investment in capex, Thermo Fisher's revenues have increased at a 12.95% CAGR between 2019 and 2024.

Seekingalpha | 1 month ago
Thermo Fisher Is Strengthening Its Long-Term Advantage

Thermo Fisher Is Strengthening Its Long-Term Advantage

Thermo Fisher's 2025 headwinds from tariffs and US research funding cuts are real but temporary, not reflective of structural weakness in its fundamentals. The company is mitigating trade impacts by investing $2B in US manufacturing, leveraging diversification and innovation, and expects headwinds to peak this year. Biopharma growth, strategic acquisitions, and rapid product innovation position TMO for long-term outperformance versus less diversified peers.

Seekingalpha | 1 month ago
Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain?

Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain?

TMO unveils spectral-enabled Attune Xenith Flow Cytometer to streamline workflows and boost research accuracy.

Zacks | 1 month ago
TMO Stock Set to Gain From the Launch of New Narcotic Analyzers

TMO Stock Set to Gain From the Launch of New Narcotic Analyzers

Thermo Fisher launches new TruNarc analyzers to help law enforcement quickly detect 1,200+ substances, boosting field safety and drug interdiction efforts.

Zacks | 1 month ago
Why Is Thermo Fisher (TMO) Down 6.1% Since Last Earnings Report?

Why Is Thermo Fisher (TMO) Down 6.1% Since Last Earnings Report?

Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 month ago
Thermo Fisher Scientific Inc. (TMO) BofA Securities 2025 Healthcare Conference (Transcript)

Thermo Fisher Scientific Inc. (TMO) BofA Securities 2025 Healthcare Conference (Transcript)

Thermo Fisher Scientific Inc. (NYSE:TMO ) BofA Securities 2025 Healthcare Conference May 13, 2025 11:40 AM ET Company Participants Marc Casper - Chairman, President & Chief Executive Officer Conference Call Participants Michael Ryskin - Bank of America Michael Ryskin To kick things off, my name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team, and I'm excited to welcome everyone to Las Vegas for our Healthcare Conference 2025 edition.

Seekingalpha | 1 month ago
Thermo Fisher: Tariffs Hit, Valuation Compensates

Thermo Fisher: Tariffs Hit, Valuation Compensates

The macro environment has clearly deteriorated, with tariffs and U.S. policy weighing on short-term earnings. Management revised EPS down ~$1, but revenue guidance held as pricing and FX helped offset volume pressure. Tariff-related headwinds are expected to be fully mitigated by 2026 through supply chain adjustments.

Seekingalpha | 1 month ago
Thermo Fisher Scientific: Tariff And Policy Impacts Look Priced In

Thermo Fisher Scientific: Tariff And Policy Impacts Look Priced In

Thermo Fisher's updated 2025 guidance shows a $1 EPS, or 4.2% hit from tariffs and government spending cuts. Thermo can mitigate the tariff issues by next year, as its scale gives it options to source from different locations. Despite short-term challenges, Thermo Fisher aims for 7-9% long-term sales growth, leveraging its diverse product range and strategic acquisitions.

Seekingalpha | 2 months ago
Thermo Fisher's Q1 Earnings Top Estimates, Revenues Beat, Stock Up

Thermo Fisher's Q1 Earnings Top Estimates, Revenues Beat, Stock Up

TMO continues to advance its growth strategy and trusted partner status with customers in the first quarter of 2025.

Zacks | 2 months ago
Loading...
Load More